🇺🇸 Summit Therapeutics Inc.SMMT

Company Update Form 8-K 16-11-2026 06:08:15 EST

Subject: 8-K Items 8.01, 9.01

Overview: The FDA issued a Complete Response Letter regarding the BLA for ivonescimab in combination with chemotherapy for certain NSCLC patients.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest